PPARD and Hepatic steatosis: In support of these pre-clinical results, liver biopsies from patients with moderate and severe hepatic steatosis showed increased VLDL receptor levels and reduced PPARβ/δ mRNA levels and DNA-binding activity compared to in control subjects.